Heron Therapeutics, Inc.
NASDAQ:HRTXBiotechnology
+$0.01 today
- Market cap
- $50.25M
- Beta
- 1.57
- P/E (TTM)
- -2.5
- EPS (TTM)
- -$0.16
Volume 3.60M
Average 2.90M
Returns on capital
Heron Therapeutics, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-140.9%
avg -92.2%
ROIC
-1.6%
avg -109.4%
ROA
-7.9%
avg -69.3%
Analysis
ROIC is currently the strongest return metric at -1.6% versus its period average of -109.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Craig Alexander Collard | Chief Executive Officer & Director | USD 1.22M | 60 | — | — |
William Forbes D. | Executive Vice President & Chief Development Officer | USD 914.89K | 64 | — | — |
Ira Duarte | Executive Vice President & Chief Financial Officer | USD 857.8K | 57 | 105.25K | 0.07% |
Mark E. Hensley | Executive Vice President & Chief Operating Officer | USD 748.85K | 43 | — | — |
John C. Arthur | Senior Vice President of Manufacturing Development | — | 60 | — | — |
Melissa Jarel | Vice President of Legal | — | — | — | — |
Brett Fleshman | Chief Business Officer | — | — | — | — |
John Aiken | Executive Director of People Management & Training | — | — | — | — |
Ryan Craig | Vice President of Marketing | — | — | — | — |
Robert Sullivan | Chief Commercial Officer | — | 48 | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Oct 31, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
No open-market purchases or sales in the last 12 months.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +12.9% | +4.0% (5yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at +12.9% over three years. Forward estimates point to Revenue at +4.0% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Heron Therapeutics, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about HRTX's management, answered from reported figures.
Who manages HRTX?
Heron Therapeutics, Inc. (HRTX) lists 10 active executives. The top listed executive is John C. Arthur, Senior Vice President of Manufacturing Development.
Are HRTX insiders buying or selling?
Recent insider activity shows net buying of $10.40M.
Continue the stock analysis
Jump to another research area for this company.